Potential Role of Borreria hispida in Ameliorating Cardiovascular Risk Factors

Borreria hispida (BHE), a weed of Rubiaceae family, is being used from time immemorial as an alternative therapy for diabetes. To evaluate the scientific background of using BHE as therapy to reduce cardiovascular risk, a group of rats were given BHE for a period of 30 days, whereas control animals were given the vehicle only. The animals were sacrificed, the hearts were isolated, and perfused with buffer. All the hearts were subjected to 30-minute ischemia followed by 2-hour reperfusion. Compared with vehicle-treated rats, BHE-treated rat hearts showed improved post-ischemic ventricular function and exhibited reduced myocardial infarct size and cardiomyocyte apoptosis. The level of cytochrome c expression and caspase 3 activation was also reduced. BHE elevated antiapoptotic proteins Bcl-2 and heme oxygenase-1 and stimulated the phosphorylation of survival protein Akt simultaneously decreasing the apoptotic proteins Bax and Src. In addition, BHE enhanced the protein expression of peroxisome proliferator-activated receptor-γ, peroxisome proliferator-activated receptor-δ, and Glut-4, probably revealing the antiobese and antidiabetic potential of BHE. These results indicate that treatment with BHE improves cardiac function and ameliorates various risk factors associated with cardiac disease, suggesting that BHE can be considered as a potential plant-based nutraceutical and pharmaceutical agent for the management of cardiovascular diseases.

[1]  L. Rochette,et al.  Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. , 2006, Cardiovascular research.

[2]  Á. Tósaki,et al.  Coenzyme Q9 provides cardioprotection after converting into coenzyme Q10. , 2008, Journal of agricultural and food chemistry.

[3]  N. Bhatt,et al.  Ayurveda and Traditional Chinese Medicine: A Comparative Overview , 2005, Evidence-based complementary and alternative medicine : eCAM.

[4]  N. Maulik,et al.  SAPKs regulation of ischemic preconditioning. , 2000, American journal of physiology. Heart and circulatory physiology.

[5]  A. Loktionov.  Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). , 2003, The Journal of nutritional biochemistry.

[6]  Martin Schuler,et al.  Cytochrome C Maintains Mitochondrial Transmembrane Potential and Atp Generation after Outer Mitochondrial Membrane Permeabilization during the Apoptotic Process , 2001, The Journal of cell biology.

[7]  Dirk Westermann,et al.  Up‐regulation of PPARγ in myocardial infarction , 2008 .

[8]  Marcy J. Balunas,et al.  Drug discovery from medicinal plants. , 2005, Life sciences.

[9]  N. Maulik,et al.  Conversion of Death Signal into Survival Signal by Redox Signaling , 2004, Biochemistry (Moscow).

[10]  G. Lip,et al.  Hemoxygenase-1 in cardiovascular disease. , 2008, Journal of the American College of Cardiology.

[11]  N. Maulik,et al.  Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. , 1995, Cardiovascular research.

[12]  D. Das,et al.  Cardioprotection with alpha-tocopheryl phosphate: amelioration of myocardial ischemia reperfusion injury is linked with its ability to generate a survival signal through Akt activation. , 2008, Biochimica et biophysica acta.

[13]  M. Gomez-Lazaro,et al.  Reactive Oxygen Species and p38 Mitogen-Activated Protein Kinase Activate Bax to Induce Mitochondrial Cytochrome c Release and Apoptosis in Response to Malonate , 2007, Molecular Pharmacology.

[14]  L. Rochette,et al.  Peroxisome proliferator-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis , 2006 .

[15]  W. Bao,et al.  In Vivo Activation of Peroxisome Proliferator-Activated Receptor-δ Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[16]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[17]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[18]  Ilya Raskin,et al.  Revisiting the ancient concept of botanical therapeutics. , 2007, Nature chemical biology.

[19]  Y Li,et al.  [Mitochondria and apoptosis]. , 2000, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[20]  L. Opie,et al.  Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. , 1998, Cardiovascular research.

[21]  Á. Tósaki,et al.  Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. , 2008, American journal of physiology. Heart and circulatory physiology.

[22]  P. Goldman.  Herbal Medicines Today and the Roots of Modern Pharmacology , 2001, Annals of Internal Medicine.

[23]  T. Hashimoto,et al.  A yeast mitochondrial ATPase inhibitor interacts with three proteins that are easy to dissociate from the mitochondrial inner membrane. , 2002, Journal of biochemistry.

[24]  J. Harborne.  Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis , 1973 .

[25]  B. P. Kota,et al.  Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. , 2005, Basic & clinical pharmacology & toxicology.

[26]  J. Schlessinger.  New Roles for Src Kinases in Control of Cell Survival and Angiogenesis , 2000, Cell.

[27]  Jean-Claude Kaplan,et al.  Genomics and medicine: an anticipation. From Boolean Mendelian genetics to multifactorial molecular medicine. , 2000, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[28]  Hong-yu Zhang.  One‐compound‐multiple‐targets strategy to combat Alzheimer's disease , 2005, FEBS letters.

[29]  B. Evers.  Indian Medicinal Plants , 1875, The Indian medical gazette.

[30]  E. Lander,et al.  On the allelic spectrum of human disease. , 2001, Trends in genetics : TIG.

[31]  N. Gorbunov,et al.  REDOX ACTIVATION OF REF‐1 POTENTIATES CELL SURVIVAL FOLLOWING MYOCARDIAL ISCHEMIA REPERFUSION INJURY , 2007, Free radical biology & medicine.

[32]  C. Rao,et al.  Ethnopharmacological Evaluation of Peristrophe bicalyculata Nees. for Anti-inflammatory and Analgesic Activity , 2003 .

[33]  L. Howells,et al.  Involvement of Nrf2, p38, B-Raf, and Nuclear Factor-κB, but Not Phosphatidylinositol 3-Kinase, in Induction of Hemeoxygenase-1 by Dietary Polyphenols , 2006, Molecular Pharmacology.

[34]  V. Regitz-Zagrosek,et al.  Up-regulation of PPARgamma in myocardial infarction. , 2008, European journal of heart failure.

[35]  T. Goodwin,et al.  Biosynthesis of spheroidene and hydroxyspheroidene in Rhodopseudomonas species: experiments with nicotine as inhibitor. , 1973, The Biochemical journal.

[36]  K. Lee,et al.  Plant-derived natural product research aimed at new drug discovery , 2008, Journal of Natural Medicines.

[37]  Kai Chen,et al.  Effect of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, on Ischemia-Reperfusion Injury in Rats , 2007, Pharmacology.

[38]  N. Maulik,et al.  Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning. , 2001, American journal of physiology. Heart and circulatory physiology.